DFI cryptocurrency saw a sharp 14.4% price increase within a single hour, rising from $0.00335 to $0.00384, which was also the highest price in its 24-hour range. Despite this spike, the overall daily gain was modest at just 0.28%, reflecting a mostly stable price over the full day. The market capitalization stood at about $3.54 million, but trading volume was very low at only $881 over 24 hours, indicating a thin market where small trades can cause significant price swings. This suggests that while DFI experienced a brief surge, its market remains relatively illiquid and volatile.
The recent sharp hourly rise in DFI cryptocurrency provides context for broader market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 00:22 WIB: out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell. Notable price changes include LUNC (Terra Classic) up 3.29% at Rp0,838 with a typical hold time of 195 days and a buy-heavy order activity of 76%, ATOM (Cosmos) up 3.25% at Rp31.747 with a typical hold time of 61 days, and UNI (Uniswap) up 3.05% at Rp129.242 with a typical hold time of 65 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
